SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
SEC Accession No. 0001176256-13-000269
Filing Date
2013-04-26
Accepted
2013-04-26 13:48:31
Documents
5
Period of Report
2013-06-12

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN ISSUER FOR APRIL 26, 2012 - AMENDMENT NO.1 nymox6kampm130612.htm 6-K/A 5200
2 LETTER TO THE SECURITIES AND EXCHANGE COMMISION exhibit99-1.htm EX-99.1 2101
3 AMENDED NOTICE OF ANNUAL GENERAL MEETING AND MANAGEMENT PROXY CIRCULAR exhibit99-2.htm EX-99.2 143547
4 exhibit99-1x1x1.jpg GRAPHIC 11302
5 exhibit99-1x7x1.jpg GRAPHIC 64691
  Complete submission text file 0001176256-13-000269.txt   256860
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 5143323222
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K/A | Act: 34 | File No.: 001-12033 | Film No.: 13786491
SIC: 2835 In Vitro & In Vivo Diagnostic Substances